168 related articles for article (PubMed ID: 14528281)
1. Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?
Altomonte M; Fonsatti E; Visintin A; Maio M
Oncogene; 2003 Sep; 22(42):6564-9. PubMed ID: 14528281
[TBL] [Abstract][Full Text] [Related]
2. Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma.
Altomonte M; Visintin A; Tecce R; Leonardi A; Calabro L; Fonsatti E; Pucillo C; Maio M
J Cell Physiol; 2004 Aug; 200(2):272-6. PubMed ID: 15174097
[TBL] [Abstract][Full Text] [Related]
3. Constitutive intracellular expression of human leukocyte antigen (HLA)-DO and HLA-DR but not HLA-DM in trophoblast cells.
Ranella A; Vassiliadis S; Mastora C; Valentina M; Dionyssopoulou E; Athanassakis I
Hum Immunol; 2005 Jan; 66(1):43-55. PubMed ID: 15620461
[TBL] [Abstract][Full Text] [Related]
4. The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells.
Giorda E; Sibilio L; Martayan A; Moretti S; Venturo I; Mottolese M; Ferrara GB; Cappellacci S; Eibenschutz L; Catricalà C; Grammatico P; Giacomini P
Cancer Res; 2003 Jul; 63(14):4119-27. PubMed ID: 12874016
[TBL] [Abstract][Full Text] [Related]
5. Coexpression of major histocompatibility complex class II with chemokines and nuclear NFkappaB p50 in melanoma: a rational for their association with poor prognosis.
Martins I; Sylla K; Deshayes F; Lauriol J; Ghislin S; Dieu-Nosjean MC; Viguier M; Verola O; Charron D; Alcaide-Loridan C; Al-Daccak R
Melanoma Res; 2009 Aug; 19(4):226-37. PubMed ID: 19574933
[TBL] [Abstract][Full Text] [Related]
6. HLA-DR signaling inhibits Fas-mediated apoptosis in A375 melanoma cells.
Aoudjit F; Guo W; Gagnon-Houde JV; Castaigne JG; Alcaide-Loridan C; Charron D; Al-Daccak R
Exp Cell Res; 2004 Sep; 299(1):79-90. PubMed ID: 15302575
[TBL] [Abstract][Full Text] [Related]
7. Focal adhesion kinase mediates human leukocyte histocompatibility antigen class II-induced signaling in gingival fibroblasts.
Yoshizawa S; Meguro M; Ohyama H; Takeuchi-Hatanaka K; Matsushita S; Takashiba S; Nishimura F
J Periodontal Res; 2007 Dec; 42(6):572-9. PubMed ID: 17956472
[TBL] [Abstract][Full Text] [Related]
8. HLA class II transgenic mice mimic human inflammatory diseases.
Mangalam AK; Rajagopalan G; Taneja V; David CS
Adv Immunol; 2008; 97():65-147. PubMed ID: 18501769
[TBL] [Abstract][Full Text] [Related]
9. Spatial separation of HLA-DM/HLA-DR interactions within MIIC and phagosome-induced immune escape.
Zwart W; Griekspoor A; Kuijl C; Marsman M; van Rheenen J; Janssen H; Calafat J; van Ham M; Janssen L; van Lith M; Jalink K; Neefjes J
Immunity; 2005 Feb; 22(2):221-33. PubMed ID: 15723810
[TBL] [Abstract][Full Text] [Related]
10. Anti-adhesive signals are mediated via major histocompatibility complex class II molecules in normal and neoplastic human B cells: correlation with B cell differentiation stage.
Ahsmann EJ; Boom SE; Lokhorst HM; Rijksen G; Bloem AC
Eur J Immunol; 1997 Oct; 27(10):2688-95. PubMed ID: 9368627
[TBL] [Abstract][Full Text] [Related]
11. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.
Souwer Y; Chamuleau ME; van de Loosdrecht AA; Tolosa E; Jorritsma T; Muris JJ; Dinnissen-van Poppel MJ; Snel SN; van de Corput L; Ossenkoppele GJ; Meijer CJ; Neefjes JJ; Marieke van Ham S
Br J Haematol; 2009 May; 145(3):334-43. PubMed ID: 19245431
[TBL] [Abstract][Full Text] [Related]
12. Associated expression of HLA class I and class II antigens on melanoma cells in surgically removed metastases.
van Duinen SG; Ruitter DJ; Ferrone S
J Pathol; 1986 Aug; 149(4):339-48. PubMed ID: 3531448
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma.
Booman M; Douwes J; Glas AM; Riemersma SA; Jordanova ES; Kok K; Rosenwald A; de Jong D; Schuuring E; Kluin PM
Clin Cancer Res; 2006 May; 12(9):2698-705. PubMed ID: 16675561
[TBL] [Abstract][Full Text] [Related]
14. The overlooked "nonclassical" functions of major histocompatibility complex (MHC) class II antigens in immune and nonimmune cells.
Altomonte M; Pucillo C; Maio M
J Cell Physiol; 1999 Jun; 179(3):251-6. PubMed ID: 10228943
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte activation via MHC class II antigens.
Mooney NA; Ziai-Talebian S; Hivroz C; Miglierina R; Grillot-Courvalin C; Charron D
Nouv Rev Fr Hematol (1978); 1990; 32(1):53-7. PubMed ID: 2349082
[TBL] [Abstract][Full Text] [Related]
16. Tissue evaluation of immune markers in endometrial and cervical carcinomas.
Lazaris ACh; Chatzigianni EB; Xidias G; Panoskaltsis TA; Thomopoulou GC; Eftychiadis CA; Michalas S; Patsouris ES
J Exp Clin Cancer Res; 2004 Jun; 23(2):269-75. PubMed ID: 15354412
[TBL] [Abstract][Full Text] [Related]
17. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men.
Holling TM; Schooten E; van Den Elsen PJ
Hum Immunol; 2004 Apr; 65(4):282-90. PubMed ID: 15120183
[TBL] [Abstract][Full Text] [Related]
18. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
Kageshita T; Ishihara T; Campoli M; Ferrone S
Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas.
López-Nevot MA; Garcia E; Romero C; Oliva MR; Serrano S; Garrido F
Exp Clin Immunogenet; 1988; 5(4):203-12. PubMed ID: 3078572
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma.
Ohnmacht GA; Marincola FM
J Cell Physiol; 2000 Mar; 182(3):332-8. PubMed ID: 10653599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
